Skip to content

Welcome to Discover Pharma! Today is : October 12, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

accelerated approval

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Karyopharm seeks FDA accelerated approval for selinexor in myelofibrosis

    Karyopharm Therapeutics has submitted an application to the FDA seeking [...]

    September 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FORE Biotherapeutics completes enrolment in registrational plixorafenib brain tumour study

    FORE Biotherapeutics has completed target enrolment in the primary central [...]

    July 8, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Brenntag and dsm-firmenich agree global GMP vitamin deal
    Categories: Clinical & Regulatory
  • Laverock Therapeutics expands into in vivo CAR-T and genetic medicine
    Categories: Advanced Therapies, Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Trixeo approved in EU for asthma
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Delivery & Formulation, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top